<DOC>
	<DOCNO>NCT02869243</DOCNO>
	<brief_summary>The purpose study evaluate feasibility safety intra-tumor interstitial therapy hBMP4 increase dos patient progressive and/or multiple recurrent Glioblastoma multiforme ( GBM ) .</brief_summary>
	<brief_title>A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients</brief_title>
	<detailed_description>This multicentre , open-label , dose escalating , Phase I study enrol approximately 18 patient progressive and/or multiple recurrent GBM , failure standard therapy receive GMP Human- recombinant Bone Morphogenetic Protein 4 via intra-tumour interstitial delivery CED . Patients undergo resection biopsy tumour , confirmation viable malignant glioma tumour cell frozen section perform institutional pathologist , intra-tumor interstitial placement neuronavigational guidance 2 3 catheter . No catheter place time resection . After resection , catheter place separate procedure several day later base upon patient 's condition determine clinical examination routine MRI scan . Patients receive intra-tumour interstitial CED increase amount hrBMP4 solution ( start dose 0.5 mg ) 1:70 gadolinium-diethylenetriamine pentaacetic acid ( Gd-DTPA ) total 44-66 ml 4-6 day discretion investigator . Gd-DTPA co-infused hrBMP4 determine extent intra-tumour interstitial drug delivery . Patients hospitalized time original surgery end infusion hrBMP4 . Patients follow duration study . The primary endpoint study monitor feasibility patient safety incidence Dose-Limiting Toxicity ( DLT ) follow intra-tumour interstitial therapy hrBMP4 determine whether Maximum Tolerated Dose ( MTD ) .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>To eligible inclusion study , patient must fulfil follow inclusion criterion ≤ 28 day prior anticipate surgery date : 1 . Malignant glioma ( WHO grade III IV ) undergo conventional treatment , include surgery ( gross total resection unintentional partial resection residual tumour ) biopsy ( residual tumour ) , and/or radiation therapy , and/or chemotherapy , and/or Temozolomide progressive and/or multiple recurrent GBM . Preoperative assessment clinical presentation CT/MRI appearance lesion identify suitable candidate . 2 . Age 1875 year . 3 . Karnofsky &gt; 70 ( see APPENDIX C : EXAMPLE OF PERFORMANCE STATUS : KARNOFSKY SCALE ) . 4 . Stable dose corticosteroid longer 4 week prior enrolment . 5 . Females childbearing potential must negative serum urine pregnancy test . Females undergone surgical sterilization postmenopausal least 2 year consider childbearing potential . 6 . Females childbearing potential male undergone surgical sterilization must agree practice form effective contraception prior entry study 1 month end infusion . Effective contraception : If female , nonlactating , negative urine pregnancy test result , plan become pregnant study , childbearing potential ( hysterectomy tubal ligation least 6 month prior entry study postmenopausal 1 year ) ; childbearing potential ( include perimenopausal woman menstrual period within one year ) must practice willing continue practice acceptable birth control screen 1 month study medication discontinue . Acceptable birth control include : 1 . Combined ( oestrogen progestogen contain ) hormonal contraception ; 2 . Associated inhibition ovulation ; oral OR intravaginal OR transdermal ; 3 . Progestogenonly hormonal contraception associate inhibition ovulation : oral OR injectable OR implantable ; 4 . Progestogenonly oral hormonal contraception , inhibition ovulation primary mode action ; 5 . Intrauterine device ( IUD ) ; 6 . Intrauterine hormonereleasing system ( IUS ) ; 7 . Bilateral tubal occlusion ; 8 . Vasectomised partner ; 9 . Sexual abstinence ; 10 . Male female condom without spermicide ; 11 . Cap , diaphragm sponge spermicide . Complies The Heads Medicines Agencies ( HMA ) Recommendations Related Contraception Pregnancy Testing Clinical Trials ( Sept 2014 ) . The definition effective contraception base judgment investigator . 7 . Ability understand willingness sign write informed consent document . To eligible inclusion study , patient must violate none follow exclusion criterion ≤ 28 day prior anticipate surgery date : 1 . Patients chemotherapy , radiotherapy antineoplastic therapy ( within 4 week 5x halflife whichever short ) prior study treatment recover Grade ≤1 return baseline acute treatmentrelated toxicity previous therapy except alopecia Grade 2 neuropathy . 2 . Patients receive investigational agent . 3 . Life expectancy &lt; 3 month 4 . Haematological dysfunction define : White blood cell ( WBC ) count &lt; 3.0 x 109/L ; Absolute neutrophil count &lt; 1.5 x 109/L ; Haemoglobin level &lt; 10.0 g/dL ; Platelet count &lt; 100 x 109/L . 5 . Liver dysfunction define : Aspartate transaminase ( AST ) &gt; 2.5 x upper limit normal ( ULN ) age gender ; Alanine transaminase ( ALT ) &gt; 2.5 x ULN age gender ; Bilirubin &gt; 1.5 x ULN age gender . 6 . Renal dysfunction define : Creatinine clearance &lt; 60 mL/min/1.73 m2 patient creatinine level institutional normal age gender . 7 . Serology indicate active infection Hepatitis B C , HIV . 8 . Significant comorbidity , include coagulation disorder . 9 . Pregnancy unwillingness practice reliable birth control . 10 . Presence another active malignancy le 2 year previously ( exception : nonmelanoma skin cancer ) . 11 . Multifocal , bilateral 12 . Midline shift 5 mm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>A malignant grow astrocytoma central nervous system</keyword>
</DOC>